Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01685255 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy
A Phase 2 study, sponsored by Incyte Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 83
- Enrollment target
NCT01685255 is a Phase 2 study that was terminated before completion, run by Incyte Corporation. The registered enrollment target is 83 participants.
The verdict
NCT01685255, a Phase 2 study, was terminated before completion, sponsored by Incyte Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 83 participants
- Enrollment target
Study Summary
This is an open-label, randomized, phase 2 study of an IDO inhibitor, INCB024360 (epacadostat) versus tamoxifen in biochemical recurrent only ovarian cancer patients following complete remission with first-line chemotherapy.
Interventions
- DRUG Epacadostat
- DRUG tamoxifen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2012-08 |
| Est. Completion | 2014-10-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01685255
The ClinicalTrials.gov registry entry for NCT01685255 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 83 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Epacadostat is the first listed.
NCT01685255 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01685255 about?
NCT01685255 is a clinical study titled "A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy". This is an open-label, randomized, phase 2 study of an IDO inhibitor, INCB024360 (epacadostat) versus tamoxifen in biochemical recurrent only ovarian cancer patients following complete remission with first-line chemotherapy.
What is the current status of trial NCT01685255?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 83 participants. The study started on 2012-08. Estimated completion is 2014-10-23.
What interventions are being tested in trial NCT01685255?
The interventions under investigation include: Epacadostat (DRUG), tamoxifen (DRUG).
Who is sponsoring clinical trial NCT01685255?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.